Aparito
Aparito is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Sponsor Avidity Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years with Late-onset Pompe Disease
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
J2A-MC-GZPO: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Participants with Obesity or Overweight with and without Type 2 Diabetes. J2A-MC-GZP1: Participants with obesity or overweight with at least 1 weight-related comorbidity, without type 2 diabetes. J2A-MC-GZP2: Participants with obesity or overweight with type 2 diabetes
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Adeno-associated Virus Serotype 8 (AAV8)-mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Patients with Late-onset OTC Deficiency
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Aparito?
The 2026-10-09 snapshot links Aparito to 5 distinct CTIS trials. Recorded services include Electronic data capture, Clinical outcome assessments, e-Diary, Video hand opening time assessment. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Aparito?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Aparito conducted?
The linked trials record locations in 10 countries, including Germany, Italy, Netherlands, France, Spain. These are trial locations, not confirmed office locations or countries where Aparito delivered services.
What can this page tell me about Aparito's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Aparito. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Aparito Limited